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The p53-inhibitory function of the oncoprotein MDM2 is regulated by a number of MDM2-binding proteins,
including ARF and ribosomal proteins L5, L11, and L23, which bind the central acidic domain of MDM2 and
inhibit its E3 ubiquitin ligase activity. Various human cancer-associated MDM2 alterations targeting the
central acidic domain have been reported, yet the functional significance of these mutations in tumor devel-
opment has remained unclear. Here, we show that cancer-associated missense mutations targeting MDM2’s
central zinc finger disrupt the interaction of MDM2 with L5 and L11. We found that the zinc finger mutant
MDM2 is impaired in undergoing nuclear export and proteasomal degradation as well as in promoting p53
degradation, yet retains the function of suppressing p53 transcriptional activity. Unlike the wild-type MDM2,
whose p53-suppressive activity can be inhibited by L11, the MDM2 zinc finger mutant escapes L11 inhibition.
Hence, the MDM2 central zinc finger plays a critical role in mediating MDM2’s interaction with ribosomal
proteins and its ability to degrade p53, and these roles are disrupted by human cancer-associated MDM2
mutations.
The mammalian p53 transcription factor mediates a major
tumor suppression pathway that is negatively controlled by the
proto-oncoprotein MDM2 (HDM2 in humans; henceforth de-
noted MDM2) and is altered in most, if not all, human cancers.
The gene for mouse Mdm2 (murine double minute 2) was
originally identified in a spontaneously transformed mouse
BALB/c cell line (13). The Mdm2 protein was found to be
responsible for transformation of NIH 3T3 and Rat2 cells
when overexpressed (13), and this transforming function is
believed to stem from its ability to bind with and inhibit the
transactivation activity of p53 (39). Subsequently, the HDM2
gene, the human homologue of Mdm2, was found to be am-
plified in over one-third of those human sarcomas that still
retain wild-type p53 (41), suggesting that overexpression of
MDM2 could be a common mechanism by which cells inacti-
vate p53. Mice with targeted deletion of the Mdm2 gene die
during early embryonic development, and this lethality can
be rescued by concomitant deletion of p53, indicating that a
major in vivo function of MDM2 is to keep p53 activity in
check (27, 33).
It is believed that MDM2 controls p53 through two mecha-
nisms: inhibition of the transcriptional activity of p53 (39) and
promotion of p53 ubiquitination and degradation (18, 29).
Mdm2 binds to and masks the N-terminal transactivation do-
main of p53 by directly interfering with the interaction between
p53 and the basal transcriptional machinery (42, 54). Mdm2
belongs to a large family of RING finger ubiquitin ligases (25).
Studies have demonstrated that Mdm2 is a ubiquitin ligase
(19) and that the ubiquitin ligase activity of Mdm2 is respon-
sible for degradation of p53 both in vitro (14, 20) and in
transfected cells (14). MDM2-mediated p53 degradation also
depends on its ability to promote p53 nuclear export (46).
Mutation of a nuclear export signal (NES) in MDM2 abolishes
its ability to shuttle p53 to the cytoplasm for degradation (46).
Similarly, blocking CRM-1 mediated nuclear export of NES-
containing proteins with leptomycin B leads to nuclear accu-
mulation and increased steady-state levels of p53 and MDM2
(15, 48). These findings suggest that, whether p53 shuttles out
of the nucleus autonomously (53, 60) or in an MDM2-depen-
dent manner (5, 16, 48), nuclear export of both MDM2 and
p53 appears to be necessary for MDM2-targeted p53 degrada-
tion in the cytoplasm (reviewed in reference 61). Adding fur-
ther complexity, enforced expression of MDM2 can also pro-
mote degradation of p53 in the nucleus, provided p53 and
MDM2 are both in the same cellular compartment (57). It was
demonstrated that low levels of MDM2 mediate p53 mono-
ubiquitination and preferentially target p53 for export to the
cytoplasm, whereas high levels of MDM2 lead to p53 poly-
ubiquitination and degradation in both the nucleus and the
cytoplasm (30). Recent reports indicate that the central acidic
domain of MDM2 is important in controlling p53 activity (34,
55). Indeed, this domain was shown to be required for p53
ubiquitination and degradation (2, 37).
MDM2 interacts with p14ARF/p19Arf (ARF thereafter),
and this interaction inhibits MDM2 and stabilizes and activates
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p53 (28, 44, 49, 62). Besides ARF, many other proteins have
been identified to interact with MDM2 (reviewed in reference
23), including the retinoblastoma protein pRb (56) and the
transcription factor E2F1 (36), both of which are prominent
regulators of the cell cycle, suggesting that MDM2 may play a
role in cell cycle regulation. MDM2 also interacts with ribo-
somal proteins L5 (9, 35), L11 (31, 59), and L23 (10, 24),
indicating that Mdm2 is involved in regulating ribosomal bio-
genesis and cell growth (4). Concomitant p53 mutation and
MDM2 overexpression within the same tumor have been
found in a small fraction of clinical human cancers (6, 32),
suggesting that MDM2 has a p53-independent tumorigenic
function. Indeed, mice overexpressing Mdm2 in a p53-null
background have a higher incidence of sarcomas than do p53-
null mice, suggesting that a mechanism other than p53 inacti-
vation exists for MDM2 to contribute to tumor development
(26). In addition to genomic amplification and overexpression
of MDM2, mutations within the MDM2 gene have been re-
ported in several types of human cancers (47, 51). Intriguingly,
many of the mutant MDM2-containing cancers retain wild-
type p53 (43). Because previous studies focused mostly on
MDM2 gene amplification and protein overexpression, the
prevalence of MDM2 mutations in human cancer is unknown
and the functional significance of these mutations has not been
characterized. In this study, we focus on several human cancer-
derived MDM2 mutations described previously. We found that
some of the mutations that target the central zinc finger of
MDM2 can specifically disrupt the interaction of MDM2 with
L11 and L5. These MDM2 mutants retain full p53-suppressive
function while escaping inhibition by ribosomal protein L11.
This study provides a potential mechanistic explanation for
human cancer-derived mutations targeting the central zinc fin-
ger domain of MDM2.
MATERIALS AND METHODS
Plasmids. The cytomegalovirus (CMV) plasmid construct CMV-p53,
pCDNA3-Myc-MDM2, CMV-MDM2, and deletion mutants thereof were de-
scribed elsewhere (21, 24, 59). Mutant pCDNA3-MDM2C305F, CMV-
MDM2C305F, and CMV-MDM2C308Y constructs were generated by PCR-medi-
ated site-directed mutagenesis with the QuikChange mutagenesis kit
(Stratagene) and verified by DNA sequencing.
Cell culture and transfection. U2OS (p53-positive) osteosarcoma, H1299 (p53
negative) lung carcinoma, Saos-2 (p53 negative) osteosarcoma, HeLa (wild-type
p53, human papillomavirus E6 [HPV-E6] positive), and MDM2/; p53/
(2KO) mouse embryonic fibroblast (MEF) cells were grown in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS),
L-Glu, and penicillin-streptomycin in 5% CO2 using a humidified incubator. Cell
transfections were carried out using the FuGENE 6 reagent (Roche).
Adenovirus and infection. Adenoviruses expressing wild-type or mutant
MDM2C305F were produced by subcloning full-length MDM2 into a transition
vector, pCR259, followed by overlap recombination. For adenovirus infection,
cells were infected with adenovirus in DMEM supplemented with 0.1% fetal
bovine serum (FBS) and incubated for 2 h in a 37°C incubator with 5% CO2.
Cells were then washed with prewarmed phosphate-buffered saline (PBS) and
replenished with fresh DMEM supplemented with 10% FBS.
Antibodies, immunofluorescence, and heterokaryon assay. Indirect immuno-
fluorescence and the heterokaryon assay have been described previously (22).
Immunostained cells were analyzed using an Olympus IX-81 microscope fitted
with a SPOT camera and software. To generate antihuman ribosomal protein L5
antiserum, an N-terminally derived L5 peptide (VIQDKNYNTPKYRMC) was
conjugated to keyhole limpet hemocyanin and used for rabbit immunization.
Subsequent purification of the antiserum was done with the Sulfolink kit
(Pierce). Generation of purified antibodies toward human ribosomal proteins
L11 and L23 has been described earlier (24, 59). Rabbit polyclonal anti-p21 and
rabbit anti-Myc were kindly provided by Yue Xiong. Anti-mouse LYAR anti-
body (50) was a gift from Lishan Su. The following antibodies were commercially
purchased: rabbit polyclonal antibody to human p53 (FL393; Santa Cruz), rabbit
polyclonal antibody to human MDM2 (N-20; Santa Cruz), p53 monoclonal
antibody DO.1 (Neomarkers), monoclonal anti-MDM2 antibody SMP14 (Neo-
markers) and 4B11 (UNC Tissue Culture and Molecular Biology Support Facil-
ity), mouse antihemagglutinin (HA) (clone 12CA5; Boehringer Mannheim),
mouse monoclonal (PC10) anti-PCNA (Neomarkers), mouse antiactin
(MAB1501; Chemicon International), mouse antitubulin (Neomarkers), and
rabbit polyclonal anti-green fluorescent protein (GFP) (Research Diagnostics).
For immunofluorescence experiments, the rhodamine red-, Cy2-, fluorescein
isothiocyanate-, and 7-amino-4-methylcoumarin-3-acetic acid (AMCA)-conju-
gated secondary antibodies were purchased commercially (Jackson Immuno-
Research Laboratories).
Luciferase assay and protein half-life measurements. Luciferase activity was
assayed using the Promega dual-luciferase assay kit as described previously (59).
To measure p53 and MDM2 half-lives, protein synthesis was blocked by addition
of cycloheximide (50 g/ml) at the indicated time points, and the levels of p53
and MDM2 proteins were analyzed by immunoblotting. Procedures for immu-
noprecipitation and immunoblotting have been described previously (12).
In vivo ubiquitination assay. To detect ubiquitinated forms of p53 in vivo,
H1299 cells were cotransfected with plasmids encoding wild-type or mutant
MDM2 together with p53 as indicated in the text and cultured for an additional
20 h. After 4 h of treatment with 10 M MG132, the cells were lysed directly in
hot sodium dodecyl sulfate (SDS) sample buffer and MDM2-mediated p53
ubiquitination was assessed by Western blotting with antibodies against p53. In
separate experiments, cells were cotransfected with MDM2 and p53 plasmids
together with a plasmid expressing HA-tagged ubiquitin (HA-Ub) for 20 h. Cells
were then treated with 10 M MG132 for 4 h prior to harvest and lysed in 1%
SDS lysis buffer followed by boiling for 10 min. The immunoprecipitation (IP)-
Western blotting assay was carried out as described above.
RESULTS
Human cancer-derived mutations in the MDM2 central zinc
finger disrupt L11 binding. Sequence alignment of MDM2
(eight mammals, frog, and zebra fish) revealed three highly
conserved areas approximately at residues 20 to 110 (numbers
according to human MDM2), 240 to 330, and 440 to 490 (Fig.
1A). The N-terminal conserved domain is believed to be im-
portant for p53 binding; the C-terminal conserved domain
contains a RING finger that is essential for MDM2’s E3 ubiq-
uitin ligase function (14, 20). The function of the central acidic
domain, including a highly conserved C4 zinc finger, is not fully
understood. Previous studies have mapped a minimal domain
around residues 284 to 347 of MDM2 for L11 interaction (59)
and residues 216 to 302 for L23 binding (10, 24). We have
recently determined that the MDM2 domain for L5 binding is
located within residues 216 to 374 (data not shown). Thus, the
three ribosomal proteins interact with MDM2 in an apparently
overlapping but nonidentical fashion (Fig. 1B). Intriguingly,
the small basic proteins that function to inhibit MDM2 and
activate p53, including ARF, L5, L11, and L23, all interact with
MDM2’s conserved central acidic domain (Fig. 1B), suggesting
that this area of MDM2 might serve as a site for receiving and
integrating various MDM2-regulatory signals into the p53
pathway (8).
Previous studies have shown that cancer-associated alterna-
tive and aberrant splicing of MDM2 mRNA occurs frequently.
Many of the splicing variants retain the N-terminal p53 binding
site and the C-terminal RING finger domain but lose the
central acidic domain, including the zinc finger (3). Cancer-
associated MDM2 gene mutations are also reported. In a study
involving 23 primary tumors of four types (osteosarcoma, non-
Hodgkin’s lymphoma, hepatocarcinoma, and leukemia), eight
samples were found to contain mutations in the coding region
VOL. 27, 2007 MDM2 ZINC FINGER MUTATION DISRUPTS L11 BINDING 1057
of MDM2 (47). Notably, most of these mutations target the
central zinc finger of MDM2, including five cases of frameshift
or nonsense mutations resulting in truncations of the zinc
finger and three cases of missense mutations altering structur-
ally important cysteine residues in the zinc finger (one affects
C305 and two affect C308, as summarized in Fig. 1B). In a
separate study involving 12 cases of liposarcoma (51), two were
found to carry MDM2 mutations at the zinc finger (one at
C308 and one at C319; Fig. 1B).
To determine if any functional consequences of MDM2
might result from these mutations, we constructed MDM2
mutants according to those identified in human cancer and
examined the MDM2 protein complex by coupled [35S]methi-
onine metabolic labeling and immunoprecipitation (35S-IP) us-
ing cell lysate from transfected U2OS cells. Comparison of
wild-type and mutant MDM2 complexes revealed several cel-
lular proteins with apparent molecular masses of 35, 32, and 20
kDa that associate specifically with the wild type but not with
any of the mutant MDM2 proteins, and a 15-kDa protein
associated with every mutant except MDM21-210, which con-
tains a deletion from amino acid 211 to amino acid 491 (Fig.
2A). To determine the identity of these MDM2-associated
proteins, a large-scale IP was carried out with extract from
U2OS cells infected with adenovirus expressing the wild-type
MDM2 (Ad-MDM2). Three of the four MDM2-binding
polypeptides were identified by mass spectrometry as the ribo-
somal proteins L5, L11, and L23, corresponding to the 35-, 20-,
and 15-kDa polypeptides, respectively (indicated in Fig. 2A),
which have been described previously (4, 9, 24, 31, 35, 59). The
identity of the 32-kDa peptide has not been established. To
determine whether any of the cancer mutations might affect
MDM2’s interaction with p53 or ARF, p53 and ARF were
FIG. 1. Cancer-derived mutations target MDM2 C4 zinc finger. (A) Diagram of the three conserved MDM2 domains corresponding to an
N-terminal p53-binding site, a central acidic region including the C4 zinc finger, and a C-terminal RING finger domain. Each vertical bar
represents a residue conserved between the species shown. Sequence alignment of the MDM2 C4 zinc finger region from 10 species is shown.
(B) Schematic representation of MDM2 structure. MDM2 mutations identified from human cancer (C305F, C308Y, positions 1 to 302 and 1 to
309) (47), C308W and C319R (51), and approximate binding areas for p53, ARF, and three ribosomal proteins are indicated.
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FIG. 2. The MDM2 zinc finger mutant fails to bind ribosomal proteins L5 and L11. (A and B) HeLa cells were transiently transfected with
plasmid DNA expressing wild-type and mutant MDM2 as indicated. Twenty-four hours after transfection, cells were metabolically labeled with
[35S]methionine for 30 min, and cell lysates were immunoprecipitated with antibody to MDM2 (SMP14). Immunoprecipitated proteins were
separated by SDS-PAGE gel and visualized by autoradiography. The molecular identities of L5, L11, and L23 were determined by protein mass
spectrometry analysis following a preparative large-scale anti-MDM2 immunoprecipitation. (C and D) U2OS cells were infected with adenoviruses
expressing either wild-type MDM2 or the MDM2C305F mutant, and interactions of MDM2 with the endogenous ribosomal proteins were examined
by IP-Western blotting. IB, immunoblotting. (E) L5, L11, and L23 do not immunoprecipitate each other but coexist in the same MDM2
immunocomplex. U2OS cells were infected with Ad-MDM2, and complex formation between MDM2 and endogenous L5, L11, and L23 was
analyzed using antibodies recognizing each of these proteins. (F) A zinc finger mutant MDM2 is able to form homo-oligomers with wild-type
MDM2. 2KO cells were transfected with Myc-tagged wild-type MDM2 and the untagged MDM2C305F mutant as indicated, and IP-Western blotting
was performed as indicated. (G) Expression of a zinc finger mutant does not interfere with the MDM2-L11 interaction. 2KO cells were
transfected with MDM2 and mutant MDM2C305F as indicated, followed by MDM2 immunoprecipitation and Western blotting for MDM2
and endogenous L11.
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FIG. 3. MDM2 zinc finger mutants are attenuated in mediating p53 degradation. (A) U2OS cells were transfected with plasmids expressing p53
alone or in combination with MDM2, MDM2C305F, or MDM2C308Y, as indicated. The levels of p53, MDM2 and tubulin (loading control) were
analyzed by Western blotting. IB, immunoblotting. (B) A p53 half-life assay in the presence of MDM2 or MDM2C305F mutant. U2OS cells were
infected with adenoviruses expressing wild-type MDM2, the MDM2C305F mutant, or a GFP control. After 24 h of infection, de novo protein
synthesis was blocked by addition of cycloheximide at 50 g/ml, and the cells were chased for 0, 1, 2, 3, and 4 h, as indicated. Virus titers were
adjusted so that cells expressed equal amounts of wild-type and mutant MDM2. Whole-cell lysates were prepared, and endogenous p53 and PCNA
levels were analyzed by Western blotting using antibodies to p53 (DO1) and PCNA (PC10). Quantification of the results for p53 in each lane was
normalized to the PCNA loading control, and the zero hour time point was set to 100%. (C) Half-life assays for MDM2 and MDM2C305F mutant.
H1299 cells (p53-negative, MDM2 undetectable) were transfected with plasmids encoding wild-type or mutant MDM2C305F. Cycloheximide (50
g/ml) was added to the cells 24 h after transfection. The cells were lysed at indicated time points, and the level of MDM2 was determined by
Western blotting. The percentage of MDM2 remaining at each time point was plotted to the right.
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coexpressed with each MDM2 mutant and the MDM2 protein
complexes were examined. As shown in Fig. 2B, none of the
cancer-derived mutations affected MDM2’s association with
either p53 or ARF. As expected, the control deletion mutant,
MDM21-210, retained binding activity toward p53 but not ARF
(Fig. 2B, lane 2). Hence, our results indicate that mutations on
or near the MDM2 central zinc finger disrupt its association
with L5 and L11, but not L23 or ARF.
To further study the function of the MDM2 zinc finger, we
generated an adenovirus expressing the C305F mutant MDM2
(Ad-C305F). We expressed the mutant and wild-type MDM2
in U2OS cells and examined the interaction of each with en-
dogenous ribosomal proteins by IP-Western blotting. Consis-
tent with the results obtained from 35S-IP, MDM2C305F did not
interact with L5 or L11 but retained the ability to interact with
L23 (Fig. 2C and D). Notably, the MDM2C305F protein mi-
grated as a single band, as opposed to the wild-type MDM2’s
two bands, on the SDS-polyacrylamide gel electrophoresis
(PAGE) gel (Fig. 2C, lane 3). The change in MDM2’s banding
pattern was most obvious in the direct Western blot, while less
distinct following an immunoprecipitation. The nature of this
banding pattern change remains to be determined. To examine
whether the three ribosomal proteins can either coexist to-
gether with MDM2 or compete for MDM2 binding, we in-
fected U2OS cells with Ad-MDM2 and examined complex
formation between MDM2 and endogenous L5, L11, and L23
by antibodies raised against each of the ribosomal proteins. We
found that L5, L11, and L23, although found together in the
large ribosomal subunit, did not interact directly with each
other in the immunoprecipitation, but could coexist together
with MDM2 in an MDM2 immunocomplex (Fig. 2E). These
results are consistent with a previous study (9). Because
MDM2 can form homo-oligomers through the interaction of
its C-terminal RING domain (52), we wanted to test whether
the zinc finger mutation might affect MDM2 homo-oligomer-
ization. Using a Myc-tagged wild-type MDM2 and a nontagged
mutant, we determined that the zinc finger mutation did not
affect MDM2’s ability to form homo-oligomers (Fig. 2F). We
then analyzed whether expression of the MDM2C305F mutant
interferes with the wild-type MDM2-L11 interaction. To
accomplish this, MDM2 and the MDM2C305F mutant were
expressed to equal levels either individually or in a 1:1 combi-
nation in MDM2/; p53/ (2KO) MEF cells, and the inter-
action of MDM2 with endogenous L11 was determined by
IP-Western blotting. We chose to use 2KO cells to avoid en-
dogenous MDM2 interference. As shown in Fig. 2G, the level
of L11 that was precipitated from cells expressing a 1:1 com-
bination of MDM2 and MDM2C305F was approximately half of
that pulled down from cells expressing 2 MDM2, indicating
that expression of the MDM2C305F mutant does not inhibit the
interaction of L11 with wild-type MDM2. Together, these data
indicate that the zinc finger mutation selectively disrupts
MDM2’s interaction with L5 and L11, but not L23, and does
not affect MDM2 homo-oligomerization.
The MDM2C305F mutant is attenuated in mediating p53
degradation. To further study the functional consequences of
the MDM2 zinc finger mutation, we examined MDM2 zinc
finger mutants in promoting p53 degradation. U2OS cells were
transfected with plasmids expressing p53 alone or in combina-
tion with MDM2, MDM2C305F, or MDM2C308Y (with both
MDM2 mutants constructed according to mutations identified
in human cancer) (47), and the levels of p53 were determined
by Western blotting. Under conditions in which overexpression
of wild-type MDM2 resulted in p53 degradation, overexpres-
sion of the zinc finger mutant MDM2 had no discernible effect
on p53 protein level (Fig. 3A). This attenuated ability of
MDM2 zinc finger mutants to induce p53 degradation was
further demonstrated by a half-life assay of endogenous p53
under the control of ectopically expressed MDM2. In this
assay, U2OS cells (p53 positive) were infected with adenovi-
ruses expressing GFP, MDM2, or MDM2C305F. Twenty-four
FIG. 4. The MDM2C305F mutant retains the ability to promote
ubiquitination of p53 and itself. (A) MDM2 and MDM2C305F mutant
promote p53 ubiquitination. H1299 cells were transfected with plas-
mids expressing p53, wild-type MDM2, or the MDM2C305F mutant as
indicated. The cells were treated with 10 M MG132 4 h before
harvesting to allow accumulation of ubiquitinated p53. Cells were then
lysed in hot SDS lysis buffer, and the expression of p53 and MDM2 was
analyzed using Western blotting with antibodies to p53 (DO1) or
MDM2 (4B11). Both wild-type MDM2 and MDM2C305F promoted
p53 ubiquitination, as evidenced by p53 Ub-ladder formation.
(B) MDM2 and MDM2C305F mutant promote self-ubiquitination. 2KO
cells were transfected with plasmids encoding wild-type MDM2 or the
MDM2C305F mutant and incubated with MG132 (10 M) for the
indicated times. Expression of MDM2 was detected by an MDM2
antibody (4B11). Both long and short exposures (Expo) of the MDM2
blot are shown.
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FIG. 5. MDM2C305F mutant is impaired in undergoing nuclear export. (A and B) MDM2 nuclear export determined by a heterokaryon assay. Saos2
cells were transiently transfected with plasmids expressing either wild-type MDM2 or the MDM2C305F mutant. One day after transfection, the cells were
fused with 2KO MEF cells by polyethylene glycol in the presence of cycloheximide (50 g/ml, to block de novo protein synthesis). MDM2 (red)
and endogenous p19Arf (green) were detected by a mouse anti-MDM2 antibody and a rabbit anti-p19Arf antibody, respectively. Formation of
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hours after infection, the cells were treated with cycloheximide.
The levels of endogenous p53 were then determined by West-
ern blotting at different time intervals, and the results were
quantified and plotted (Fig. 3B). Without MDM2 overexpres-
sion, ectopically expressed p53 had a half-life of approximately
200 min in U2OS cells (Fig. 3B, top panel). Coexpression of
MDM2 reduced the half-life of p53 to approximately 100 min
(middle panel). Coexpression of the MDM2C305F mutant, in
contrast, did not reduce p53’s half-life (bottom panel). The
attenuated p53 degradation by the mutant MDM2 was further
confirmed with 35S-metabolic labeling in an independent ex-
periment and in other cell lines, including 2KO (data not
shown). Thus, whereas wild-type MDM2 promotes p53 degra-
dation, the MDM2C305F mutant is impaired in doing so. We
also examined the effect of the zinc finger mutation on the
protein stability of MDM2 itself. We used H1299 cells (p53
negative, MDM2 undetectable) for the experiment to circum-
vent potential effects from endogenous p53. Interestingly, we
found that while the wild-type MDM2 had an estimated half-
life of about 40 min, the mutant had a significantly longer
half-life of about 90 min (Fig. 3C), indicating that the mutant
protein is more stable than the wild type. In summary, these
experiments find that the MDM2 zinc finger is critical in me-
diating MDM2-induced p53 degradation as well as MDM2
self-degradation.
The MDM2C305F mutant can promote p53 ubiquitination.
Both p53 and MDM2 are degraded through ubiquitin-medi-
ated proteolysis, and MDM2 functions as the E3 ligase for
both. To determine whether the attenuated p53 degradation is
due to an inability of the MDM2C305F mutant to promote p53
ubiquitination, we carried out an in vivo p53 ubiquitination
assay. H1299 cells were transfected with plasmids expressing
MDM2 and p53. The cells were treated with the proteasome
inhibitor MG132 prior to lysis to allow ubiquitinated proteins
to accumulate. Subsequently, the cells were lysed in hot SDS
lysis solution (hot SDS solution protects ubiquitinated protein
species from deubiquitination), and the p53 protein was de-
tected directly by straight Western blotting with an anti-p53
antibody. To our surprise, the MDM2C305F mutant, although
attenuated in promoting p53 degradation, was as active as the
wild-type MDM2 in promoting p53 ubiquitination (Fig. 4A).
The levels of p53 ubiquitination were essentially equal in sam-
ples transfected with MDM2 or the MDM2C305F mutant, in-
dicating that the zinc finger mutation did not affect MDM2’s
E3 ubiquitin ligase activity toward p53. The ability of the
MDM2C305F mutant to ubiquitinate p53 was further confirmed
by an IP-Western blot assay of polyubiquitinated p53 in an-
other experiment (see below in Fig. 6). To gain further insight
into the E3 ubiquitin ligase function of the MDM2C305F mu-
tant, we examined self-ubiquitination of the mutant MDM2 in
2KO cells. As shown in Fig. 4B, in the absence of endogenous
p53 and Mdm2, the MDM2C305F mutant was fully capable of
promoting self-ubiquitination. We have noticed that treatment
of the cells with MG132 dramatically stabilized wild-type
MDM2 (Fig. 4B, compare lane 1 with lane 2 in the short
exposure), but less so for the MDM2C305F mutant (Fig. 4B,
compare lane 4 with lane 5 in the short exposure), which is in
agreement with the observed longer half-life of the
MDM2C305F mutant than the wild type MDM2 (Fig. 3C).
Hence, our data show that the integrity of the zinc finger is
essential for MDM2 to efficiently induce degradation of p53
and itself, but is not strictly required for ubiquitination of
either one.
The MDM2C305F mutant is impaired in nuclear export. It
has been shown that MDM2-mediated p53 ubiquitination
occurs in both the nucleus (16) and the cytoplasm (40) and
that MDM2 nucleocytoplasmic shuttling contributes to p53
degradation (46). The uncoupling of normal p53 ubiquitina-
tion with an attenuated degradation by the MDM2C305F mu-
tant prompted us to examine whether the mutant MDM2 was
unable to undergo nucleocytoplasmic shuttling, thus trapping
p53 in the nucleus. For this purpose, we carried out an inter-
species heterokaryon assay to examine directly the nucleocy-
toplasmic shuttling of mutant MDM2 and p53. Human Saos2
(MDM2 undetectable) cells were transiently transfected
with plasmids expressing either wild-type MDM2 or the
MDM2C305F mutant. One day after transfection, the cells were
fused with 2KO MEF cells by polyethylene glycol in the pres-
ence of cycloheximide (50 g/ml, to block de novo protein
synthesis). 2KO cells express high levels of p19Arf that can be
used to distinguish donor human nuclei from recipient mouse
nuclei in heterokaryons. Accumulation of the MDM2 protein
in the mouse nuclei in a heterokaryon will indicate that the
protein has been exported out of the human nucleus into the
shared cytoplasm and then imported into the mouse nucleus.
Using this technique, we detected relocalization of wild-type
MDM2 to the mouse nucleus in a significant portion of het-
erokaryons (Fig. 5A and C). In contrast, in the majority of
heterokaryons expressing the MDM2C305F mutant, the protein
did not enter the mouse nucleus (Fig. 5B and C). Thus, the
MDM2C305F mutant is deficient in nuclear export. To deter-
mine whether the nuclearly trapped MDM2C305F mutant might
affect p53 nuclear export, we expressed wild-type MDM2 or
the MDM2C305F mutant together with p53 in a heterokaryon
assay. p53 (green) and MDM2 (red) were detected by rabbit
anti-p53 and mouse anti-MDM2 antibodies, respectively, and
the mouse nuclei were identified by a rat anti-LYAR antibody,
which specifically detects mouse nucleoli with high sensitivity
(50). In samples expressing wild-type MDM2, p53 was readily
detected in most mouse nuclei in the heterokaryons (Fig. 5D
heterokaryons is shown in phase-contrast images, with human (h) and mouse (m) nuclei indicated. Relocalization of MDM2 to the mouse nucleus
was seen in a significant portion of heterokaryons expressing wild-type MDM2 but not mutant MDM2, as shown with quantification in panel C.
DAPI, 4,6-diamidino-2-phenylindole. (D and E) MDM2 and p53 nuclear export determined by a heterokaryon assay. Saos2 cells were transfected
with plasmids expressing wild-type MDM2 or the MDM2C305F mutant together with a p53-expressing plasmid. The fusion was performed as
described above. MDM2 (red) and p53 (green) were detected by mouse anti-MDM2 and rabbit anti-p53 antibodies, respectively. The mouse nuclei
were detected by a rat anti-LYAR (blue) antibody. Formation of heterokaryons is shown in phase-contrast images, with human (h) and mouse (m)
nuclei indicated. Relocalization of MDM2 and p53 to the mouse nucleus was seen in about half of the heterokaryons examined, as shown with
quantification in panel F.
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and F). In contrast, in samples expressing the MDM2C305F
mutant, a significantly higher proportion of heterokaryons
showed retention of p53 in the Saos2 nucleus (Fig. 5E and F),
suggesting that the nuclear export-defective MDM2C305F mu-
tant trapped p53 in the nucleus. Thus, the impaired nuclear
export of p53 by coexpression of the MDM2C305F mutant is, at
least in part, an explanation for the defect in p53 degradation.
The MDM2C305F mutant retains the function of repressing
p53 transcriptional activity. Because MDM2 is able to repress
the transcriptional activity of p53 through binding to and mask-
ing the p53 N-terminal transactivation domain (42, 54), we
wanted to determine whether the MDM2C305F mutant retains
p53-suppressive activity. To this end, U2OS cells were coin-
fected with p53 together with Ad-MDM2 or Ad-MDM2C305F,
and the levels of endogenous p21 were examined by Western
blotting. Figure 6A showed that p21 was activated by p53, and
this activation was eliminated by coexpression of either MDM2
or MDM2C305F, indicating that the MDM2C305F mutant re-
tained the capability of suppressing p53. To determine whether
the MDM2C305F mutant was equally effective as the wild-type
MDM2 in repressing p53, we adjusted the ratio of p53 to
MDM2 in the transfections so that the p53 protein was not
degraded and its activity was partially suppressed. Intriguingly,
we found that the MDM2C305F mutant appeared to be more
effective than the wild-type protein in suppressing p53 (Fig. 6B,
lane 3). To study the zinc finger mutant MDM2-imposed p53
suppression in further detail, we examined p53 transcriptional
activity using a p53-responsive reporter construct, pGL13-Luc
(11), in a luciferase assay (Fig. 6C). Cotransfection of pGL13-
Luc with a p53-expressing plasmid led to an average six- to
sevenfold increase in luciferase activity, which was normalized
as 100% of p53-dependent transactivation. Coexpression of
p53 with either wild-type MDM2 or MDM2C305F decreased
the luciferase activity in a dose-dependent manner. We noticed
that, again, the MDM2C305F mutant consistently exhibited
stronger inhibition than did the wild-type MDM2 at each dos-
age tested. We speculate that the higher p53-inhibitory activity
of the MDM2C305F mutant might be related to its nuclear
retention and longer half-life. Together, these results indicate
that mutations in the zinc finger motif, while impairing
MDM2-mediated p53 degradation, do not reduce and may
actually enhance, MDM2’s ability to repress p53’s transactiva-
tion activity, suggesting a potential explanation for the pres-
ence of MDM2 zinc finger mutations in human cancers.
The MDM2C305F mutant escapes from L11 inhibition. Pre-
vious studies have shown that the interaction of ribosomal
protein L11 with MDM2 inhibits MDM2’s p53-suppressive
function (31, 59) and plays a critical role in mediating growth
inhibition-induced p53 activation (4). To determine whether
the MDM2C305F mutant, by breaking off L11 binding, might
have escaped L11-imposed inhibition, we examined the effect
of L11 overexpression on MDM2-mediated p53 repression
using a luciferase assay. As shown in Fig. 7A, under conditions
in which wild-type MDM2 effectively repressed p53-dependent
transactivation of the pGL13-Luc reporter (column 4), coex-
pression of L11 restored up to 70% of p53 activity (column 5).
In contrast, L11 did not relieve MDM2C305F-imposed p53 re-
pression (columns 6 and 7), indicating that MDM2C305F is
insensitive to L11 inhibition, supporting the hypothesis that the
mutant MDM2 escapes from L11 inhibition.
To gain further insight into the mechanism of the L11-
imposed MDM2 inhibition that is abrogated by the zinc finger
mutation, we carried out an in vivo p53 ubiquitination assay by
transfecting U2OS cells with plasmid DNA expressing HA-Ub
together with p53, MDM2, ARF, and L11 in a variety of
combinations. One day after transfection, cells were lysed in
hot SDS lysis solution, and p53 was pulled down with an anti-
FIG. 6. The MDM2C305F mutant retains the ability to repress p53
transcriptional activity. (A) Suppression of p53-induced endogenous
p21 by MDM2. U2OS cells were infected with adenoviruses expressing
MDM2 or MDM2C305F. Twenty-four hours after infection, cell lysates
were prepared and separated by SDS-PAGE. Different portions of the
same blot were immunoblotted with antibodies recognizing MDM2,
p53, and p21 as indicated. A nonspecific protein detected by the
MDM2 antibody serves as a loading control. (B) Apparent higher
p53-suppressive activity of MDM2C305F mutant. U2OS cells were
transfected with equal amounts of total DNA expressing p53 and
MDM2 (or MDM2C305F) in a 1:1 ratio. This ratio of p53 and MDM2
plasmid transfection does not trigger p53 degradation, making a com-
parative analysis of p21 suppression possible. Levels of MDM2, p53,
and endogenous p21 were determined by Western blotting. (C) Sup-
pression of p53 transcriptional activity by MDM2 in a luciferase assay.
U2OS cells were cotransfected with a p53-responsive pGL13-Luc re-
porter plasmid along with plasmid expressing the indicated proteins.
Twenty-four hours after transfection, clarified cell lysates prepared
from each transfected cell population were incubated with a luciferase
assay buffer, and optical density at 595 nm was determined with a
luminometer. The luciferase activity for each sample was normalized
to -galactosidase activity for transfection efficiency.
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p53 antibody and separated on an SDS-PAGE gel. HA-Ub-
conjugated p53 was then detected with an anti-HA antibody.
As shown in Fig. 7B, polyubiquitinated p53 was detected in
abundance when MDM2 was cotransfected (lane 7). The ubiq-
uitinated p53 was not detected when ARF or L11, both of
which inhibit the ubiquitin ligase activity of MDM2, were in-
cluded in the transfection (lanes 8 and 9). Conversely, in agree-
ment with previous data showing that MDM2C305F is capable
FIG. 7. The MDM2C305F mutant escapes negative regulation from ribosomal protein L11. (A) L11 reverses MDM2-suppressed p53 transcriptional
activity in a luciferase assay. pGL13-Luc reporter plasmid was cotransfected with plasmids expressing the indicated proteins in U2OS cells. The luciferase
assay was carried out as described above. (B) The MDM2C305F mutant escapes inhibition of L11 but not ARF in a p53 ubiquitination assay. U2OS cells
were transfected with plasmids in various combinations as indicated. Twenty hours after transfection, cells were treated with proteasome inhibitor MG132
(50 M) for 4 h prior to lysis. Clarified cell lysate was immunoprecipitated with anti-p53 (-p53) antibody (FL393), and the immunoprecipitates were
resolved by SDS-PAGE followed by immunoblotting (IB) with anti-HA (-HA) antibody. -Myc, anti-Myc antibody.
VOL. 27, 2007 MDM2 ZINC FINGER MUTATION DISRUPTS L11 BINDING 1065
of promoting p53 monoubiquitination (Fig. 4A), a smaller but
still considerable amount of polyubiquitinated p53 was de-
tected when MDM2C305F was cotransfected (lane 10). Strik-
ingly, however, the MDM2C305F mutant-induced p53 ubiquti-
nation was inhibited effectively by ARF (lane 11) but only
partially by L11 (lane 12), indicating that the mutant MDM2C305F
escapes specifically from L11- but not ARF-imposed inhibition.
DISCUSSION
Sequence alignment has revealed three highly conserved
areas in the MDM2 protein, located at the N terminus, the C
terminus and the central acidic domain (Fig. 1A). The N-
terminal conserved domain is essential for p53 binding,
whereas the C terminus possesses a RING finger domain re-
sponsible for MDM2’s E3 ubiquitin ligase activity. However,
the function of the central acidic domain, which includes a
highly conserved C4 zinc finger, has been elusive. MDM2 in-
teracts with multiple ribosomal proteins, including, but not
necessarily limited to, L5, L11, and L23. Although there are
variations in published reports regarding the exact interacting
sequences on MDM2 for each of the three ribosomal proteins,
all point to the central acidic domain (Fig. 1B), indicating that
this area of MDM2 could have a function that is modulated by
ribosomal protein interaction. A potential biological role for
the MDM2 zinc finger was suggested by the identification of
human cancer-derived mutations that specifically target the
cysteine residues in MDM2’s zinc finger motif (47, 51). In our
present study, we examined two of these cancer-associated
MDM2 mutations and have identified an essential role for the
zinc finger of MDM2. We show that a mutation at a zinc-
coordinating cysteine residue specifically disrupts MDM2
binding with ribosomal proteins L5 and L11, but not L23 or
ARF, and the mutant MDM2 remains fully functional in bind-
ing with and suppressing the activity of p53. It has been shown
previously that the interaction of ribosomal proteins with
MDM2 mediates signals of ribosomal stress and growth inhi-
bition to induce a p53-dependent cell cycle arrest (4). This
regulation of p53 is thought to occur through the binding of
ribosomal proteins to the central acidic domain of MDM2,
thereby inhibiting MDM2’s E3 ubiquitin ligase function and
consequently stabilizing and activating p53 (9, 24, 31, 59).
Thus, MDM2 with mutations disrupting ribosomal protein
binding would evade ribosomal stress-induced growth inhibi-
tion, which could explain the origin of these zinc finger muta-
tions in human cancer.
Why the zinc finger is critical for MDM2 to interact with L5
and L11 is unclear, but it is likely that a correct structure
formed by the C4 zinc finger is a minimal requirement for the
binding. A recently solved solution structure of the MDM2 C4
zinc finger shows that residues 297 to 329 (numbers based on
human MDM2 sequence) form a compact globular fold in
which a zinc ion is coordinately bound by the four cysteine
residues (C305, C308, C319, and C322) (58). The MDM2 C4
zinc finger is a member of the RanBP2/NZF-like zinc finger
family, which also includes functionally diverse proteins such
as RanBP2, Npl4, Vps36p, Znf265, and EWS (38). The C4 zinc
finger structure in RanBp2/NZF proteins has been implicated
in RNA binding and direct interaction with ubiquitin (1, 38).
However, the MDM2 C4 zinc finger failed to interact with the
ubiquitin molecule in vitro (38). It is likely that the C305F
mutation in MDM2 leads to a collapse of the zinc finger fold
(58). Our results showing that the C4 zinc finger integrity is
required for binding with ribosomal proteins L11 and L5 is
consistent with this notion (Fig. 2). With the availability of the
MDM2 C4 zinc finger solution structure, it is possible to use
additional site-directed mutagenesis of nonstructural zinc fin-
ger amino acids to compare the roles of the MDM2 and
MDMX C4 zinc fingers, which would be of particular interest
given the lack of conservation between MDM2 and MDMX in
some of the nonstructural amino acids in the zinc finger do-
main.
We have found that the MDM2C305F mutant, when ex-
pressed ectopically, has a delayed protein turnover (Fig. 3C).
Although both MDM2 and MDM2C305F are relatively short-
lived, the mutant has a half-life twice as long as that of wild-
type MDM2 (90 min versus 40 min). This can be attributed, at
least in part, to the attenuated ability of the MDM2C305F mu-
tant to undergo nuclear export (Fig. 5). How the zinc finger
mutation, which is quite far from MDM2’s NES sequence (see
Fig. 1B), attenuates MDM2 nuclear export is unknown. The
observation that the mutation disrupts the L5-L11 interaction
brings about an interesting possibility: L5 and L11 may help
MDM2 to undergo nuclear export. This idea may not be sur-
prising, given that ribosomal proteins are known to travel back
and forth between the nucleolus and cytoplasm and that L5 has
been shown to be involved in shuttling of rRNA out of the
nucleus (17). On the other hand, because we have found that
a zinc finger mutation significantly affects the MDM2 confor-
mation such that it migrates as a single band rather than a
doublet on the SDS-PAGE gel (Fig. 2C), we cannot exclude
that conformational changes in MDM2 might affect its nuclear
export. A long-lived, nuclearly trapped MDM2 may gain an
advantage in binding to and suppressing the function of p53.
This notion is in line with the observation that the zinc finger
mutant MDM2 was originally found in human cancers and is
reported to accumulate to high levels in these tumors (43, 51).
It has been shown previously that deletion of residues 222 to
272 attenuates MDM2-mediated degradation, but not ubiquiti-
nation, of both MDM2 itself and p53 (2), indicating a mecha-
nism that could disintegrate MDM2-induced p53 ubiquitina-
tion from degradation. We have found that a single mutation
in the zinc finger did not affect MDM2-induced p53 ubiquiti-
nation appreciably, but rather attenuated MDM2-induced p53
degradation (Fig. 3 and 4). A possible explanation for the
apparently unchanged ubiquitination and the slower turnover
of p53 in the presence of the MDM2 mutant could be that the
mutant MDM2, although able to ubiquitinate p53, is itself
impaired in nuclear export (Fig. 5) and thus traps p53 in the
nucleus and attenuates its degradation.
It is conceivable that the ribosomal protein-MDM2-p53 con-
nection represents a signaling pathway that functions to safe-
guard the integrity of ribosomal biogenesis in higher-order
eukaryotic cells in order to coordinate cellular growth with
proliferation. In this regard, mutations in genes that affect the
function of this pathway could arise in human cancers, granting
an advantage to cells in escaping p53 surveillance. MDM2 gene
amplification is a predominant mechanism described for
MDM2 oncogenic activation and has been detected in many
types of human cancers, including soft tissue sarcomas (41) and
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brain tumors (7, 45). Thus far, most studies examining MDM2
oncogenic alterations have focused on analyzing MDM2 gene
amplification and alternative splicing (3). Our findings that
tumor-derived mutations targeting the central zinc finger dis-
rupt the negative regulation of MDM2 by L11 represent a
novel putative mechanism for MDM2 oncogenic activation.
Five different types of tumors represented by these limited
studies contain missense or nonsense mutations in MDM2 that
disrupt its interaction with L5 and L11. The possibility formally
exists that the prevalence of gene mutation-based MDM2 on-
cogenic activation may be underestimated. Based on the cur-
rent and previous studies, it is tempting to propose that the
MDM2-p53 feedback loop has evolved to safeguard cells from
undergoing uncontrolled growth and proliferation through
three major signaling pathways: the phosphorylation of MDM2
and p53 by a variety of kinases signals DNA damage, the
ARF-MDM2 interaction signals oncogenic insults, and the ri-
bosomal protein-MDM2 interaction signals malfunctions in
ribosomal biogenesis.
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